Life Sciences

Global Diabetes and Obesity Drugs Market to 2022 — Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment

1 zUea0JOWZXrNQtR8NDsf7Q

Global Diabetes and Obesity Drugs Market to 2022 — Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment

Summary-

Diabetes is a chronic metabolic disease characterized by hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia in diabetic patients is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). Obesity, meanwhile, is defined as abnormal or excessive body fat accumulation that presents a risk to health.

GET 20% DISCOUNT ON THIS REPORT

A current global rise in T2DM prevalence is intrinsically linked with the current global rise in obesity. The rapidly increasing global obesity prevalence has resulted in it being considered a global epidemic, and there is a vast and growing global patient population potentially requiring pharmacotherapeutic treatment.

Historically anti-obesity therapeutics have been out of favor due to safety concerns. Both diabetes and obesity products are commonly associated with cardiovascular adverse events, and this is further compounded by concerns relating to cancer development through long-term usage of anti-obesity products. This has resulted in an unmet need for products with favorable safety and efficacy profiles, particularly in the case of obesity.

Scope-

– What are the current treatment options for diabetes and obesity?
– What are the common molecular targets of pipeline therapies, and how strongly do they overlap with the current market?
– Will the pipeline address unmet needs such as a lack of safe treatment options for diabetes and obesity patients?
– Which late-stage pipeline products are likely to impact the current market?
– How are revenues of key companies, targets and molecule types anticipated to change over the forecast period?

Download Free Report Sample @

https://www.24marketreports.com/request-sample/global-diabetes-and-obesity-drugs-market-to-2022—insulins-and-gpcrs-retain-commercial-prominence-while-high-unmet-need-remains-in-weight-loss-treatment

Table Of Content-

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 6

2 Introduction 9

2.1 Therapy Area Introduction 9

2.2 Symptoms 11

2.3 Etiology and Pathophysiology 11

3 Key Marketed Products 22

3.1 Overview 22

3.2 Diabetes — Top Eight Key Marketed Products 23

3.3 Obesity Overview 31

4 Pipeline Landscape Assessment 36

4.1 Overview 36

4.2 Pipeline Development Landscape 37

4.3 Molecular Targets in the Pipeline 40

4.4 Clinical Trials 43

For More Details Visit @

https://www.24marketreports.com/life-sciences/global-diabetes-and-obesity-drugs-market-to-2022—insulins-and-gpcrs-retain-commercial-prominence-while-high-unmet-need-remains-in-weight-loss-treatment

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s